["{\n\"step_by_step_thinking\": \"First, let's analyze the patient's lipid profile. The HDL is 32 mg/dL, LDL is 126 mg/dL, and TG is 276 mg/dL. We can see that the patient has low HDL levels and high triglyceride levels. According to the study [Quantitative and qualitative serum lipoprotein analysis. Part 2. Studies in male survivors of myocardial infarction], low HDL cholesterol values are related to higher VLDL triglyceride values. Since the patient's VLDL triglycerides are elevated, we can infer that their LDL triglycerides are also likely high.\n\nNext, let's consider the patient's clinical presentation. They had a recent myocardial infarction and are 60 years old, which suggests they have an increased cardiovascular risk.\n\nFinally, let's look at the treatment options. Rosuvastatin is a statin that primarily targets LDL cholesterol, while fenofibrate is a fibrate that primarily targets VLDL triglycerides. Since the patient has elevated LDL triglycerides and low HDL levels, we would want to target both issues.\n\nGiven these considerations, we can conclude that the patient would benefit from combination therapy with rosuvastatin and fenofibrate.\",\n\"answer_choice\": \"A: Rosuvastatin + Fenofibrate\"\n}"]